Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index; 3 of the 22 sources its claims cite were checked for support.

Understanding Equivalence and Noninferiority Testing

Open access
Walker, Esteban, Nowacki, Amy S. · 2011 · Journal of General Internal Medicine

Abstract

Increasingly, the goal of many studies is to determine if new therapies have equivalent or noninferior efficacies to the ones currently in use. These studies are called equivalence/noninferiority studies, and the statistical methods for their analysis require only simple modifications to the traditional hypotheses testing framework. Nevertheless, important and subtle issues arise with the application of such methods. This article describes the concepts and statistical methods involved in testing equivalence/noninferiority. The aim is to enable the clinician to understand and critically assess the growing number of articles utilizing such methods.

Overview

CoChat Summary

TL;DR

This article explains equivalence and noninferiority testing, emphasizing that these require reversing traditional hypotheses and defining an equivalence margin δ in advance. It reviews the two one-sided test (TOST) procedure, sample-size implications, and common pitfalls such as interpreting a nonsignificant difference test as evidence of equivalence.

Key findings

  • Equivalence is established at significance level α when a (1−2α)×100% confidence interval for the difference in efficacies is contained within (−δ, δ); for α=0.05, this means using a 90% confidence interval. Noninferiority is established when the lower limit of that interval is above −δ when higher is better, or when the upper limit is below δ when lower is better.
  • In the HIV example, the equivalence margin was δ=12 percentage points; response rates were 50.8% for abacavir and 51.3% for indinavir, with a reported 95% CI for the difference of (−9, 8), which lies within (−12, 12), so equivalence was declared at the 0.025 significance level.
  • In OASIS-5, the noninferiority margin for relative risk was 1.185; observed risks were 5.8% for fondaparinux and 5.7% for enoxaparin [RR=1.01, 95% CI (0.90, 1.13)], and because the upper CI limit was below 1.185, noninferiority was established. For major bleeding, fondaparinux showed superiority [RR=0.52, 95% CI (0.44, 0.61)].
  • Barker et al. found contradictory results between traditional two-sided tests and TOST in 9 of 21 comparisons using α=0.05 and an equivalence margin of 5 percentage points. Le Henanff identified 162 equivalence/noninferiority reports from 2003–2004, with about 80% not justifying their equivalence margin and 28% not considering the margin in sample-size calculation.

Methods

  • This is a conceptual/methodological review or tutorial, not a primary empirical study. It describes hypotheses, the TOST procedure, equivalence margins, sample size, measures of effect, intention-to-treat versus per-protocol analysis, and reporting recommendations.
  • It uses published trial examples—the abacavir-lamivudine-zidovudine versus indinavir-lamivudine-zidovudine HIV trial (n=562), OASIS-5, and Barker et al.’s National Immunization Survey vaccination-coverage comparisons—to illustrate equivalence and noninferiority testing.
  • Sample-size illustrations were calculated with PASS 8; for true proportions of 0.28 and 0.33, achieving 0.80 power at α=0.05 required 26,185 per group for δ=0.06 and 535 per group for δ=0.12.

Limitations

  • The paper does not state limitations of its own review; it states that the literature contains much confusion, lack of uniformity, and lack of transparency in terminology, and cites deficiencies in reporting of equivalence/noninferiority trials.
  • Evident from the text: this is a narrative educational article with selected examples, not a systematic review or meta-analysis, and it reports no formal search strategy or primary data collection.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11606-010-1513-8

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

3 Valid · 12 Not valid · 15 Not checked · 40 Own results and interpretations

18 more claims

Create a free account to see all 70 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 36
  • It may state two separate claims as one. 19

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 16 references

Cited by

See all 751

Metadata

Authors
Walker, E., & Nowacki, A. S.
Affiliations
Cleveland Clinic (US)
Corresponding author
Walker, Esteban
Venue
Journal of General Internal Medicine
Published
2010-09-21
Volume
26
Issue
2
Pages
192-196
ISSN
  • 0884-8734 (ISSN-L)
  • 1525-1497
OpenAlex
W2086898699
Cited by
751
References
16
Citations by year
2026: 52 · 2025: 34 · 2024: 63 · 2023: 51 · 2022: 52 · 2021: 67 · 2020: 66 · 2019: 82 · 2018: 83 · 2017: 68 · 2016: 55 · 2015: 46 · 2014: 21 · 2013: 6 · 2012: 2
FWCI
3.00
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of General Internal Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
  • Physical Sciences › Mathematics › Statistics and Probability › Probability and Statistical Research
Keywords
equivalence testing, non-inferiority testing, hypothesis testing, clinical trial design, treatment efficacy comparison, statistical interpretation
MeSH terms
Humans, Research Design, Therapeutic Equivalency, Sample Size, Comprehension

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-11-03, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-03 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Understanding Equivalence and Noninferiority Testing. https://app.cochat.ai/papers/10.1007/s11606-010-1513-8
The paper
Walker, E., & Nowacki, A. S. (2011). Understanding Equivalence and Noninferiority Testing. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-010-1513-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.